Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Applied Nanotechnology in Chronic Human Disease Management
share announcement

Applied Nanotechnology in Chronic Human Disease Management

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 10412

Special Issue Editor

Dr. Murtaza M. Tambuwala

E-Mail Website
Guest Editor
School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine BT52 1SA, UK
Interests: nanoparticles; anti-inflamamtory; anti-cancer; anti-microbials; drug delviery; biomedical engineering; 3D printing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanotechnology has been known to produce significant scientific and technological advances in diverse fields, including medicine and physiology. This exciting field of research can be defined as the science and engineering involved in the design, synthesis, characterization, and application of materials and devices whose smallest functional unit is on the nanometer scale, ranging from a few to several hundred nanometers.
The aim of this Special Issue is to include original research and review manuscript describing the preparation, characterization, functionalization, and therapeutic applications in the treatment and diagnosis of chronic human diseases with the objective of improving the therapeutic outcome and quality of life of patients suffering from diseases such as:

  • Heart disease
  • Cancer
  • Chronic lung disease
  • Stroke
  • Alzheimer’s
  • Diabetes
  • Kidney disease
  • Inflammatory bowel disease

Authors are invited to submit original and review articles covering all aspects of nanocarriers designed for effective drug delivery and diagnosis.

Dr. Murtaza. M. Tambuwala
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • surface functionalization
  • cancer
  • cardiovascular
  • targeted delivery
  • liposomes
  • natural compounds
  • diabetes
  • inflammation

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 4253 KiB  
Article
Effect of UV Irradiation (A and C) on Casuarina equisetifolia-Mediated Biosynthesis and Characterization of Antimicrobial and Anticancer Activity of Biocompatible Zinc Oxide Nanoparticles
by Amna Komal Khan, Sullivan Renouard, Samantha Drouet, Jean-Philippe Blondeau, Iram Anjum, Christophe Hano, Bilal Haider Abbasi and Sumaira Anjum
Pharmaceutics 2021, 13(11), 1977; https://doi.org/10.3390/pharmaceutics13111977 - 22 Nov 2021
Cited by 19 | Viewed by 2763
Abstract
The green synthesis of nanoparticles has emerged as a simple, safe, sustainable, reliable and eco-friendly protocol. Among different types of NPs, green-synthesized zinc oxide NPs (ZnONPs) show various promising biological uses due to their interesting magnetic, electrical, optical and chemical characteristics. Keeping in [...] Read more.
The green synthesis of nanoparticles has emerged as a simple, safe, sustainable, reliable and eco-friendly protocol. Among different types of NPs, green-synthesized zinc oxide NPs (ZnONPs) show various promising biological uses due to their interesting magnetic, electrical, optical and chemical characteristics. Keeping in view the dependence of the therapeutic efficacy of NPs on their physico-chemical characteristics, the green synthesis of ZnONPs using Casuarina equisetifolia leaf extract under UV-A and UV-C light was carried out in this study. UV-irradiation helped to control the size and morphology of ZnONPs by exciting the electrons in the photoactive compounds of plant extracts to enhance the bio-reduction of ZnO into ZnONPs. C. equisetifolia leaf extract was found enriched with phenolic (2.47 ± 0.12 mg GAE/g DW) and flavonoid content (0.88 ± 0.28 mg QE/g DW) contributing to its 74.33% free-radical scavenging activity. FTIR spectra showed the involvement of polyphenols in the bio-reduction, stabilization and capping of ZnONPs. Moreover, SEM-EDX and XRD analyses showed great potential of UV-C light in yielding smaller (34–39 nm) oval-shaped ZnONPs, whereas UV-A irradiation resulted in the formation of fairly spherical 67–71 nm ZnONPs and control ZnONPs were of mixed shape and even larger size (84–89 nm). Green-synthesized ZnONPs, notably CE-UV-C-ZnONPs, showed promising anti-bacterial activities against Bacillus subtilis, Pseudomonas fluorescens and Pseudomonas aeruginosa. Moreover, ZnONPs also enhanced ROS production which led to a significant loss of mitochondrial membrane potential and activated caspase-3 gene expression and caspase-3/7 activity in human hepatocellular carcinoma (HepG2) cells. CE-UV-C-ZnONP treatment reduced HepG2 cell viability to as low as 36.97% owing to their unique shape and smaller size. Lastly, ZnONPs were found to be highly biocompatible towards brine shrimp and human red blood cells suggesting their bio-safe nature. This research study sheds light on the plausible role of UV radiation in the green synthesis of ZnONPs with reasonable control over their size and morphology, thus improving their biological efficacy. Full article
(This article belongs to the Special Issue Applied Nanotechnology in Chronic Human Disease Management)
►▼ Show Figures

Figure 1

Review

Jump to: Research

33 pages, 5481 KiB  
Review
Emerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update
by Vijay Mishra, Pallavi Nayak, Mayank Sharma, Aqel Albutti, Ameen S. S. Alwashmi, Mohammad Abdullah Aljasir, Noorah Alsowayeh and Murtaza M. Tambuwala
Pharmaceutics 2021, 13(10), 1568; https://doi.org/10.3390/pharmaceutics13101568 - 27 Sep 2021
Cited by 13 | Viewed by 6885
Abstract
The occurrence of diabetes mellitus (DM) is increasing rapidly at an accelerating rate worldwide. The status of diabetes has changed over the last three generations; whereas before it was deemed a minor disease of older people but currently it is now one of [...] Read more.
The occurrence of diabetes mellitus (DM) is increasing rapidly at an accelerating rate worldwide. The status of diabetes has changed over the last three generations; whereas before it was deemed a minor disease of older people but currently it is now one of the leading causes of morbidity and mortality among middle-aged and young people. High blood glucose-mediated functional loss, insulin sensitivity, and insulin deficiency lead to chronic disorders such as Type 1 and Type 2 DM. Traditional treatments of DM, such as insulin sensitization and insulin secretion cause undesirable side effects, leading to patient incompliance and lack of treatment. Nanotechnology in diabetes studies has encouraged the development of new modalities for measuring glucose and supplying insulin that hold the potential to improve the quality of life of diabetics. Other therapies, such as β-cells regeneration and gene therapy, in addition to insulin and oral hypoglycemic drugs, are currently used to control diabetes. The present review highlights the nanocarrier-based drug delivery systems and emerging treatment strategies of DM. Full article
(This article belongs to the Special Issue Applied Nanotechnology in Chronic Human Disease Management)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop